APA (7th ed.) Citation

Wunderink, R. G., Bruno, C., Martin-Loeches, I., Kollef, M., Timsit, J., Yu, B., . . . Rhee, E. G. (2019). 2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP). Open Forum Infectious Diseases, 6, S760. https://doi.org/10.1093/ofid/ofz360.1904

Chicago Style (17th ed.) Citation

Wunderink, Richard G., et al. "2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) Vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP)." Open Forum Infectious Diseases 6 (2019): S760. https://doi.org/10.1093/ofid/ofz360.1904.

MLA (9th ed.) Citation

Wunderink, Richard G., et al. "2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) Vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP)." Open Forum Infectious Diseases, vol. 6, 2019, p. S760, https://doi.org/10.1093/ofid/ofz360.1904.